688319 Stock Overview
Chengdu Olymvax Biopharmaceuticals Inc. engages in the research and development, production, and sale of human vaccines.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 5/6 |
| Past Performance | 2/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for 688319 from our risk checks.
Chengdu Olymvax Biopharmaceuticals Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥7.55 |
| 52 Week High | CN¥25.00 |
| 52 Week Low | CN¥7.06 |
| Beta | 0.51 |
| 1 Month Change | -26.77% |
| 3 Month Change | -42.67% |
| 1 Year Change | -63.04% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -81.08% |
Recent News & Updates
Chengdu Olymvax Biopharmaceuticals Inc. (SHSE:688319) Shares May Have Slumped 25% But Getting In Cheap Is Still Unlikely
Apr 18
These 4 Measures Indicate That Chengdu Olymvax Biopharmaceuticals (SHSE:688319) Is Using Debt Extensively
Mar 26Shareholder Returns
| 688319 | CN Biotechs | CN Market | |
|---|---|---|---|
| 7D | -8.2% | -3.8% | -0.4% |
| 1Y | -63.0% | -26.7% | -16.2% |
Return vs Industry: 688319 underperformed the CN Biotechs industry which returned -26.4% over the past year.
Return vs Market: 688319 underperformed the CN Market which returned -17.6% over the past year.
Price Volatility
| 688319 volatility | |
|---|---|
| 688319 Average Weekly Movement | 10.3% |
| Biotechs Industry Average Movement | 8.0% |
| Market Average Movement | 8.9% |
| 10% most volatile stocks in CN Market | 12.7% |
| 10% least volatile stocks in CN Market | 5.4% |
Stable Share Price: 688319's share price has been volatile over the past 3 months.
Volatility Over Time: 688319's weekly volatility (10%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2009 | 467 | Shaowen Fan | www.olymvax.com |
Chengdu Olymvax Biopharmaceuticals Inc. engages in the research and development, production, and sale of human vaccines. It offers adsorbed tetanus vaccine; Hib conjugate vaccine; Group A streptococcus vaccine; and AC conjugate vaccine. The company also provides vaccines for haemophilus influenzae type b; group A and C meningococcal; and Staphylococcus aureus, which is in Phase 3 clinical trial.
Chengdu Olymvax Biopharmaceuticals Inc. Fundamentals Summary
| 688319 fundamental statistics | |
|---|---|
| Market cap | CN¥3.07b |
| Earnings (TTM) | CN¥17.41m |
| Revenue (TTM) | CN¥496.12m |
176.1x
P/E Ratio6.2x
P/S RatioIs 688319 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 688319 income statement (TTM) | |
|---|---|
| Revenue | CN¥496.12m |
| Cost of Revenue | CN¥0 |
| Gross Profit | CN¥496.12m |
| Other Expenses | CN¥478.71m |
| Earnings | CN¥17.41m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Apr 26, 2024
| Earnings per share (EPS) | 0.043 |
| Gross Margin | 100.00% |
| Net Profit Margin | 3.51% |
| Debt/Equity Ratio | 19.6% |
How did 688319 perform over the long term?
See historical performance and comparison